Document is current
Any future updates will be listed below
-
Authors
McLaughlin, Vallerie
Alsumali, Adnan https://orcid.org/0000-0002-5139-3583
Liu, Rongzhe https://orcid.org/0000-0001-8316-6089
Klok, Rogier https://orcid.org/0000-0001-6584-4886
Martinez, Eliana C.
Nourhussein, Iman https://orcid.org/0000-0003-3271-7439
Bernotas, David
Chevure, Jestinah
Pausch, Christine https://orcid.org/0000-0002-1866-9015
De Oliveira Pena, Janethe
Lautsch, Dominik https://orcid.org/0000-0003-3803-1817
Hoeper, Marius M. https://orcid.org/0000-0001-9086-2293
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04576988 at ClinicalTrials.govDocuments that mention this clinical trial
Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH)
https://doi.org/10.1007/s12325-023-02684-x
Advances in the management of pulmonary arterial hypertension
https://doi.org/10.1136/jim-2021-002027
Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model
https://doi.org/10.1007/s12325-025-03241-4
-
Funding
Funding for this research was provided by:
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
- License Information
-
More Information
Article History
Received: 15 August 2023
Accepted: 8 September 2023
First Online: 18 October 2023
Declarations
:
: Rongzhe Liu, Iman Nourhussein, and David Bernotas are employees (or were employees during conduct of this study) of OPEN Health, which received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to conduct the study. Adnan Alsumali, Janethe de Oliveira Pena, Rogier Klok, Dominik Lautsch, Jestinah Chevure and Eliana Martinez are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and hold stock in Merck & Co., Inc., Rahway, NJ, USA. Vallerie McLaughlin is a consultant for Aerovate, Altavant Sciences, Bayer, CVS Caremark, CorVista Health, Gossamer Bio, Janssen, Merck, and United Therapeutics; and has received grants from Aerovate, Altavant Sciences, Merck, Gossamer Bio, Janssen, and SoniVie; and received stocks from Clene. Christine Pausch has nothing to disclose. Marius M. Hoeper is a consultant and speaker for Acceleron Pharma, Inc, Actelion, AOP Orphan Pharmaceuticals, Bayer, Ferrer, GlaxoSmithKline, Janssen, and MSD.
: This study relied on previously conducted studies and did not involve any new studies requiring the direct participation of human subjects; thus, ethics board approval was not required.
